Abstract
In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.
References
1.
Goyal
G
, Tazi
A
, Go
RS
, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
. Blood
. 2022
;139
(17
):2601
-2621
.2.
Allen
CE
, Beverley
PCL
, Collin
M
, et al. The coming of age of Langerhans cell histiocytosis
. Nat Immunol
. 2020
;21
(1
):1
-7
.3.
Héritier
S
, Emile
J-F
, Barkaoui
M-A
, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy
. J Clin Oncol
. 2016
;34
(25
):3023
-3030
.4.
Kemps
PG
, Zondag
TCE
, Arnardóttir
HB
, et al. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
. Blood Adv
. 2023
;7
(4
):664
-679
.5.
Xiao
Y
, van Halteren
AGS
, Lei
X
, et al. Bone marrow–derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis
. Blood
. 2020
;136
(19
):2188
-2199
.6.
Acosta-Medina
AA
, Abeykoon
JP
, Go
RS
, et al. BRAF testing modalities in histiocytic disorders: comparative analysis and proposed testing algorithm. Am J Clin Pathol
. Published online 17 July 2023. http://doi.org/10.1093/ajcp/aqad076.7.
Teepen
JC
, van Leeuwen
FE
, Tissing
WJ
, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy
. J Clin Oncol
. 2017
;35
(20
):2288
-2298
.8.
Zanwar
S
, Abeykoon
JP
, Dasari
S
, et al. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
. Blood Cancer J
. 2022
;12
(6
):97
.9.
Jouenne
F
, Chevret
S
, Bugnet
E
, et al. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement
. Eur Respir J
. 2020
;55
(2
):1901190
.10.
Cao
X
, Duan
M
, Zhao
A
, et al. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis
. Am J Hematol
. 2022
;97
(2
):203
-208
.11.
Stathi
D
, Yavropoulou
MP
, Allen
CE
, et al. Prevalence of the BRAF V600E mutation in Greek adults with Langerhans cell histiocytosis
. Pediatr Hematol Oncol
. 2022
;39
(6
):540
-548
.12.
Ma
J
, Laird
JH
, Chau
KW
, Chelius
MR
, Lok
BH
, Yahalom
J
. Langerhans cell histiocytosis in adults is associated with a high prevalence of hematologic and solid malignancies
. Cancer Med
. 2019
;8
(1
):58
-66
.13.
Goyal
G
, Parikh
R
, Richman
J
, et al. Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult Langerhans cell histiocytosis
. Leuk Res
. 2023
;126
:107032
.14.
Bagnasco
F
, Zimmermann
SY
, Egeler
RM
, et al. Langerhans cell histiocytosis and associated malignancies: a retrospective analysis of 270 patients
. Eur J Cancer
. 2022
;172
:138
-145
.15.
Papo
M
, Diamond
EL
, Cohen-Aubart
F
, et al. High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
. Blood
. 2017
;130
(8
):1007
-1013
.16.
Kemps
PG
, Hebeda
KM
, Pals
ST
, et al. Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation
. J Pathol Clin Res
. 2021
;7
(1
):10
-26
.17.
Chen
W
, Wang
J
, Wang
E
, et al. Detection of clonal lymphoid receptor gene rearrangements in Langerhans cell histiocytosis
. Am J Surg Pathol
. 2010
;34
(7
):1049
-1057
.© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal